United States - English - NLM (National Library of Medicine)

e.r. squibb & sons, l.l.c. - deucravacitinib (unii: n0a21n6rau) (deucravacitinib - unii:n0a21n6rau) - sotyktu™ is indicated for the treatment of moderate-to-severe plaque psoriasis in adults who are candidates for systemic therapy or phototherapy. limitations of use : sotyktu is not recommended for use in combination with other potent immunosuppressants. sotyktu is contraindicated in patients with a history of hypersensitivity reaction to deucravacitinib or to any of the excipients in sotyktu [see warnings and precautions (5.1)] .         available data from case reports on sotyktu use during pregnancy are insufficient to evaluate a drug-associated risk of major birth defects, miscarriage, or adverse maternal or fetal outcomes. in animal reproduction studies, no effects on embryo-fetal development were observed with oral administration of deucravacitinib to rats and rabbits during organogenesis at doses that were at least 91 times the maximum recommended human dose (mrhd) of 6 mg once daily (see data) . all pregnancies have a background risk of birth defect, loss, or other adverse outcomes. the background ris

Australia - English - Department of Health (Therapeutic Goods Administration)

bristol-myers squibb australia pty ltd - deucravacitinib, quantity: 6 mg - tablet, film coated - excipient ingredients: croscarmellose sodium; magnesium stearate; hypromellose acetate succinate; microcrystalline cellulose; silicon dioxide; lactose; titanium dioxide; purified talc; iron oxide yellow; iron oxide red; polyvinyl alcohol; macrogol 3350 - sotyktu is indicated for the treatment of adult patients with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy.

European Union - English - EMA (European Medicines Agency)

bristol-myers squibb pharma eeig - deucravacitinib - psoriasis - immunosuppressants - treatment of moderate-to-severe plaque psoriasis in adults.

Canada - English - Health Canada

bristol-myers squibb canada - deucravacitinib - tablet - 6mg - deucravacitinib 6mg

Israel - English - Ministry of Health

bristol, myers squibb (israel) limited, israel - deucravacitinib - film coated tablets - deucravacitinib 6 mg - deucravacitinib - sotyktu is indicated for the treatment of moderate to severe plaque psoriasis in adults who are candidates for systemic therapy

Bangladesh - English - DGDA (Directorate General of Drug Administration)

everest pharmaceuticals ltd. - deucravacitinib - tablet - 6 mg

Bangladesh - English - DGDA (Directorate General of Drug Administration)

ziska pharmaceuticals ltd. - deucravacitinib - tablet - 6 mg

Singapore - English - HSA (Health Sciences Authority)

bristol-myers squibb (singapore) pte. ltd. - deucravacitinib - tablet, film coated - deucravacitinib 6.00 mg

Japan - English - すりの適正使用協議会 RAD-AR Council, Japan

bristol-myers squibb - deucravacitinib - light yellowish red, round tablet, diameter: approx. 8.1 mm, thickness: approx. 4.1 mm, weight: approx. 206 mg

Saudi Arabia - English - SFDA (Saudi Food and Drug Authority)- الهيئة العامة للغذاء والدواء

bristol-myers squibb, united states - deucravacitinib - film-coated tablet - 6 mg,